CY1108605T1 - Αλλαντοτοξινη στην θεραπεια ή στην προληψη της ακμης - Google Patents

Αλλαντοτοξινη στην θεραπεια ή στην προληψη της ακμης

Info

Publication number
CY1108605T1
CY1108605T1 CY20081101377T CY081101377T CY1108605T1 CY 1108605 T1 CY1108605 T1 CY 1108605T1 CY 20081101377 T CY20081101377 T CY 20081101377T CY 081101377 T CY081101377 T CY 081101377T CY 1108605 T1 CY1108605 T1 CY 1108605T1
Authority
CY
Cyprus
Prior art keywords
allantotoxin
acne
acme
prevention
treatment
Prior art date
Application number
CY20081101377T
Other languages
English (en)
Inventor
Dana L Suskind
Ann H Tilton
Mary L Caire
Original Assignee
Board Of Supervisors Of Louisiana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Supervisors Of Louisiana filed Critical Board Of Supervisors Of Louisiana
Publication of CY1108605T1 publication Critical patent/CY1108605T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η Αλλαντοτοξίνη μπορεί να χρησιμοποιηθεί ώστε να αναστείλει τον καταρράκτη γεγονότων που οδηγούν στην ακμή. Τα αποτελέσματα των προκαταρκτικών μελετών είναι δραματικά. Χωρίς να επιθυμούμε δέσμευση σε αυτή τη θεωρία, πιστεύεται ότι ή αλλαντοτοξίνη, επιτυγχάνει αυτό το αποτέλεσμα μέσω παρασυμπαθητικών δράσεων, αναστέλλοντας την δραστηριότητα του ιδρωτοποιού αδένα, διειγείτοντας την κινητοποίηση των κερατινοκυττάρων, μέσω αντί-φλεγμονωδών και πιθανών αντιανδρογονικών δράσεων. Η αλλαντοτοξίνη μπορεί να διαδραματίσει ένα σημαντικό ρόλο στην ελάττωση και συχνά στην πρόληψη του σχηματισμού ακμής.
CY20081101377T 2001-07-27 2008-11-27 Αλλαντοτοξινη στην θεραπεια ή στην προληψη της ακμης CY1108605T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30820501P 2001-07-27 2001-07-27
EP02791543A EP1411978B1 (en) 2001-07-27 2002-07-25 Botulinum toxin in the treatment or prevention of acne

Publications (1)

Publication Number Publication Date
CY1108605T1 true CY1108605T1 (el) 2014-04-09

Family

ID=23192997

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101377T CY1108605T1 (el) 2001-07-27 2008-11-27 Αλλαντοτοξινη στην θεραπεια ή στην προληψη της ακμης

Country Status (15)

Country Link
US (1) US7226605B2 (el)
EP (1) EP1411978B1 (el)
JP (1) JP4138651B2 (el)
KR (1) KR100602308B1 (el)
CN (1) CN1258381C (el)
AT (1) ATE406910T1 (el)
AU (1) AU2002355730B2 (el)
CA (1) CA2451923C (el)
CY (1) CY1108605T1 (el)
DE (1) DE60228723D1 (el)
DK (1) DK1411978T3 (el)
ES (1) ES2312651T3 (el)
NZ (1) NZ531389A (el)
PT (1) PT1411978E (el)
WO (1) WO2003011333A1 (el)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
EP2272340B1 (en) 2002-08-19 2018-03-14 Ira Sanders Botulinum toxin
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7824693B2 (en) * 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US7666435B2 (en) * 2002-08-19 2010-02-23 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
JP2007528351A (ja) * 2003-03-06 2007-10-11 ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド 慢性の霰粒腫および麦粒腫のボツリヌス毒素による治療
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1729821B1 (en) * 2004-03-03 2013-07-17 ReVance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA3031270A1 (en) 2004-03-03 2005-12-22 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20050220821A1 (en) 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US6991789B2 (en) 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7897147B2 (en) 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
RU2007136616A (ru) 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) Композиция и способ для местного применения и чрескожного введения ботулинового токсина
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
BRPI0613631A8 (pt) * 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
US8318181B2 (en) 2005-12-01 2012-11-27 University Of Massachusetts Lowell Botulinum nanoemulsions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7824694B2 (en) 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US9061025B2 (en) 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
KR101518077B1 (ko) 2006-12-01 2015-05-28 안테리오스, 인코퍼레이티드 펩티드 나노입자 및 이의 용도
CN101583274A (zh) * 2006-12-29 2009-11-18 雷文斯治疗公司 使用反向序列hiv-tat多肽的运输分子
AU2007340162B2 (en) * 2006-12-29 2013-08-01 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
ES2660906T3 (es) 2007-05-31 2018-03-26 Anterios, Inc. Nanopartículas de ácido nucleico y usos de las mismas
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
US20110212157A1 (en) * 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
CA2774951C (en) 2009-09-24 2014-12-16 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
US10035820B2 (en) 2012-04-13 2018-07-31 Lubrizol Advanced Materials, Inc Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
CN105451710A (zh) 2013-03-22 2016-03-30 利普泰股份公司 用于治疗和/或护理皮肤、粘膜和/或指甲的外泌多糖
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9649266B2 (en) 2014-05-01 2017-05-16 Anterios, Inc. Methods to treat, prevent, and improve skin conditions
WO2015168562A1 (en) * 2014-05-01 2015-11-05 Anterios, Inc. Demonstrable efficacy across or within patient populations
WO2016154020A1 (en) * 2015-03-20 2016-09-29 The Regents Of The University Of California Methods for reducing sebum production and/or excretion
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
EP3728295A1 (en) * 2017-12-20 2020-10-28 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders
WO2019226599A1 (en) * 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
US11191819B2 (en) 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
EP3660509B1 (en) 2018-11-29 2022-03-09 Hugel Inc. A cell-based method for determining an activity of botulinum toxin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4885282A (en) * 1987-07-02 1989-12-05 Thornfeldt Carl R Treatment of hyperhidrosis, ichthyosis and wrinkling
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
JPH11501517A (ja) * 1995-03-16 1999-02-09 クノル アクチエンゲゼルシャフト 細胞を製出するためおよび創傷治療用の定義された新規酵素混合物
KR20010089347A (ko) * 1998-10-27 2001-10-06 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 상처 치료 증진 방법
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US20030021775A1 (en) * 2001-07-27 2003-01-30 Ramot University Authority For Applied Research & Industrial Development Ltd. Device for and method of controlled enzymatic removal and retrieval of tissue
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
EP2272340B1 (en) * 2002-08-19 2018-03-14 Ira Sanders Botulinum toxin

Also Published As

Publication number Publication date
ATE406910T1 (de) 2008-09-15
KR100602308B1 (ko) 2006-07-18
US20050074466A1 (en) 2005-04-07
KR20040030820A (ko) 2004-04-09
EP1411978A1 (en) 2004-04-28
WO2003011333A1 (en) 2003-02-13
DE60228723D1 (de) 2008-10-16
PT1411978E (pt) 2008-11-28
CN1543354A (zh) 2004-11-03
CN1258381C (zh) 2006-06-07
CA2451923C (en) 2009-10-20
AU2002355730B2 (en) 2007-09-13
JP2004538310A (ja) 2004-12-24
US7226605B2 (en) 2007-06-05
NZ531389A (en) 2005-08-26
EP1411978B1 (en) 2008-09-03
JP4138651B2 (ja) 2008-08-27
DK1411978T3 (da) 2009-01-05
CA2451923A1 (en) 2003-02-13
ES2312651T3 (es) 2009-03-01
EP1411978A4 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
CY1108605T1 (el) Αλλαντοτοξινη στην θεραπεια ή στην προληψη της ακμης
DE69931766D1 (de) Antitumorale mittel
ATE288749T1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
DE69710224T2 (de) Behandlung von neurodegenerativen zuständen mittels nimesulide
DE69636997D1 (de) HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
TR199701073T1 (xx) Protein kinaz C inhibit�rleri.
ATE361082T1 (de) Pharmazeutische zusammensetzung aus komplexen kohlenhydraten deren anwendung
NO20054988L (no) Preparater og metoder for behandling av cancer
ATE234090T1 (de) Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz
PT705100E (pt) Guanidinas substituidas terapeuticas
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
DE69818939D1 (de) Rosaceae extrakt als bradykinin-antagonist
BR0212576A (pt) Método para o tratamento de distúrbios da pele
NO20031648L (no) Farmasöytiske lösninger av modafinilforbindelser
DE60132008D1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
ATE395061T1 (de) Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie
DK1558620T3 (da) Rutheniumkomplekser med anticancervirkning
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
NO20001758L (no) FremgangsmÕter og blandinger for behandling av leddgikt
MX9203739A (es) Complejo organico de oro aplicado topicamente.
DE60313474D1 (de) Behandlung von dyskinesie